| 1280 |
Centers for Disease Control and Prevention |
Html |
en |
Sugar-Sweetened Beverage Consumption Among Adults - 18States, 2012 |
Gayathri S. Kumar, MD1,2, Liping Pan, MD2, Sohyun Park, PhD2, Seung Hee Lee-Kwan, PhD1,2, Stephen Onufrak, PhD2, Heidi M. Blanck, PhD2 (Author affiliations at end of text). |
| Gayathri S. Kumar | 0.394424 |
| highest prevalence | 0.410929 |
| fruit drink consumption | 0.749956 |
| SSB data | 0.385551 |
| noninstitutionalized U.S. adult | 0.351463 |
| optional SSB module | 0.40601 |
| healthful beverages | 0.347178 |
| energy drinks | 0.368747 |
| state-specific prevalence | 0.346778 |
| SSB consumption | 0.659399 |
| total SSB intake | 0.409993 |
| Seung Hee Lee-Kwan | 0.351832 |
| weight management | 0.347137 |
| Heidi M. Blanck | 0.351549 |
| United States apportion | 0.351682 |
| regular soda | 0.918367 |
| U.S. adult population | 0.417942 |
| fruit drink questions | 0.370182 |
| Behavioral Risk Factor | 0.348465 |
| regular soda consumption | 0.489348 |
| higher SSB consumption | 0.49054 |
| chronic health conditions | 0.38925 |
| fruit drinks | 0.761998 |
| preventive health practices | 0.350206 |
|
| SSB energy intake | 0.429665 |
| community venues | 0.346995 |
| median response rate | 0.346711 |
| states | 0.412812 |
| consumption frequency | 0.365795 |
| daily consumption | 0.415106 |
| diet soda | 0.375049 |
| non-Hispanic blacks | 0.487223 |
| health departments | 0.346342 |
| daily regular soda | 0.447459 |
| coffee drinks | 0.373221 |
| 24-ounce soda | 0.366683 |
| chronic diseases | 0.371738 |
| BRFSS response rates | 0.347734 |
| SSB marketing | 0.386433 |
| U.S. adults | 0.427848 |
| response rates | 0.363872 |
| cell phone survey | 0.348077 |
| added sugars | 0.423231 |
| NHANES response rates | 0.345348 |
| daily ssb consumption | 0.520678 |
| Chronic Disease Prevention | 0.370432 |
| SSB questions | 0.394757 |
| SSB types | 0.389322 |
|
CLICK HERE |
| 7952 |
Centers for Disease Control and Prevention |
Html |
en |
Preventing Chronic Disease | Provider Compliance WithGuidelines for Management of Cardiovascular Risk in HIV-InfectedPatients - CDC |
Compliance with National Cholesterol Education Program Adult Treatment Panel III (NCEP) guidelines has been shown to significantly reduce incident cardiovascular events. We investigated physicians’ compliance with NCEP guidelines to reduce cardiovascular disease (CVD) risk in a population infected with HIV. |
| low HDL-C | 0.689856 |
| major risk factors | 0.60647 |
| Infectious Disease Society | 0.64288 |
| cholesterol education program | 0.716745 |
| relevant financial relationships | 0.649817 |
| myocardial infarction | 0.612048 |
| cardiovascular risk factors | 0.611012 |
| national cholesterol education | 0.715385 |
| Adult Treatment Panel | 0.680833 |
| Interagency HIV Study | 0.609839 |
| HOPS patients | 0.626404 |
| Disease Control | 0.627195 |
| pharmacologic treatment | 0.608961 |
| CVD risk | 0.69913 |
| Clin Infect Dis | 0.731603 |
| cardiovascular events | 0.690715 |
| blood pressure | 0.678854 |
| risk factors | 0.785708 |
| Joan S. Chmiel | 0.651482 |
| patients | 0.843763 |
| Kenneth A. Lichtenstein | 0.648344 |
| mm Hg | 0.657426 |
| metabolic syndrome | 0.671447 |
| NCEP treatment goals | 0.604873 |
| moderately high risk | 0.666221 |
|
| CrossRef | 0.607644 |
| treatment goals | 0.62086 |
| study | 0.626288 |
| antiretroviral therapy | 0.612651 |
| contemporary HOPS patients | 0.622576 |
| Program Adult Treatment | 0.644943 |
| Immune Defic Syndr | 0.679354 |
| Clinical Trials Group | 0.63866 |
| HIV Outpatient Study | 0.62384 |
| incident cardiovascular events | 0.661301 |
| Acquir Immune Defic | 0.679357 |
| cardiovascular risk | 0.62722 |
| high CVD risk | 0.603304 |
| Adult AIDS Clinical | 0.63684 |
| AIDS Clinical Trials | 0.636426 |
| Education Program Adult | 0.631608 |
| Scott D. Holmberg | 0.623916 |
| NCEP guidelines | 0.697747 |
| low HDL-C levels | 0.619101 |
| Framingham risk calculation | 0.603455 |
| et al | 0.94617 |
| coronary heart disease | 0.784288 |
| HIV-infected patients | 0.738976 |
| HIV infection | 0.70484 |
|
CLICK HERE |
| 11753 |
Centers for Disease Control and Prevention |
Html |
en |
MMWR News Synopsis: October 9, 2014 | CDC Media Relations | CDC |
MMWR – Morbidity and Mortality Weekly Report CDC public health news, press releases, government public health news, medical and disease news, story ideas, photos. |
| half | 0.458641 |
| data | 0.500185 |
| emergency department visits | 0.750959 |
| screen patients | 0.594555 |
| significant role | 0.582049 |
| migration patterns | 0.570657 |
| across-the-board gaps | 0.577041 |
| OPR | 0.726884 |
| alcohol involvement | 0.635421 |
| prescription drugs | 0.588326 |
| new CDC analysis | 0.746844 |
| fda.hhs.gov | 0.437258 |
| viral suppression | 0.912732 |
| drug abuse-related ED | 0.741693 |
| overdose deaths | 0.62192 |
| overdose increases | 0.61498 |
| Jeff Ventura | 0.615098 |
| Drug Abuse Warning | 0.744466 |
| opioid pain relievers | 0.82994 |
| alcohol | 0.65422 |
| benzodiazepines | 0.505083 |
| problematic substance | 0.613418 |
| diagnosis | 0.460356 |
| problematic alcohol | 0.651651 |
| age groups | 0.691765 |
|
| HIV treatment | 0.681359 |
| Media Team | 0.588829 |
| Jeff.ventura | 0.437274 |
| HUMAN SERVICES | 0.571791 |
| Latinos | 0.649721 |
| geographic differences | 0.567985 |
| Medical Monitoring Project | 0.722735 |
| new infections | 0.567573 |
| proportion | 0.483745 |
| Drug Administration | 0.614831 |
| linkage | 0.47047 |
| National HIV Surveillance | 0.816492 |
| U.S. clinical guidelines | 0.707291 |
| benzodiazepine abuse | 0.840494 |
| public health burden | 0.748554 |
| important markers | 0.572872 |
| U.S. DEPARTMENT | 0.567033 |
| benzodiazepine drug-related deaths | 0.851349 |
| retention | 0.460107 |
| Food | 0.435934 |
| primary health care | 0.764469 |
| Interventions | 0.469408 |
| risk | 0.501795 |
| language barriers | 0.574339 |
|
CLICK HERE |
| 12215 |
Centers for Disease Control and Prevention |
Html |
en |
Notes from the Field: Fatal Rat-Bite Fever in a Child - SanDiego County, California, 2013 |
Jessica K. Adam, MD1,2,3, Aiden K. Varan, MPH2,3,4, Alice L. |
| California San Diego | 0.42206 |
| additional RBF case | 0.514199 |
| Alice L. Pong | 0.383917 |
| pet rats | 0.514462 |
| San Diego County | 0.658487 |
| Pet rat owners | 0.411002 |
| RBF incidence | 0.441759 |
| California Office | 0.303012 |
| San Diego | 0.902296 |
| white blood cells | 0.371047 |
| rat-bite fever | 0.368769 |
| RBF | 0.573549 |
| untreated RBF illnesses | 0.520694 |
| Zoonotic Infectious Diseases | 0.482778 |
| oropharyngeal tissue | 0.302487 |
| rat breeder | 0.326529 |
| Eric C. McDonald | 0.386122 |
| spirillary fever | 0.330024 |
| National Center | 0.351185 |
| pet rat | 0.494469 |
| Territorial Epidemiologists Applied | 0.356112 |
| rat cages | 0.324227 |
| San Diego Health | 0.702239 |
| median patient age | 0.381666 |
| state public health | 0.359977 |
|
| Human Services Agency | 0.709931 |
| 1Epidemic Intelligence Service | 0.355291 |
| Child — San | 0.337571 |
| American Veterinary Medical | 0.368833 |
| Infectious Diseases Pathology | 0.368451 |
| Statewide Health Planning | 0.3652 |
| Jessica K. Adam | 0.527993 |
| previously healthy male | 0.377847 |
| S. moniliformis | 0.698285 |
| polymerase chain reaction | 0.688262 |
| San Diego Medical | 0.41542 |
| Pediatric Infectious Diseases | 0.364197 |
| persistent fever | 0.345488 |
| Oropharyngeal swabs | 0.310024 |
| joint pain | 0.364623 |
| wild rats | 0.341802 |
| RBF symptoms | 0.43789 |
| complete blood count | 0.373023 |
| potentially fatal illness | 0.361533 |
| rat secretions | 0.329965 |
| appropriate exposure history | 0.359655 |
| rapid laboratory confirmation | 0.343946 |
| Aiden K. Varan | 0.396444 |
| streptobacillary fever | 0.330087 |
|
CLICK HERE |
| 12306 |
Centers for Disease Control and Prevention |
Html |
en |
Interim Recommendations for Ambulance Service Providers inWest African Ebola-Affected Areas | Ebola Hemorrhagic Fever |CDC |
null |
| ambulance team | 0.705099 |
| decontamination | 0.395084 |
| biohazard bags | 0.385358 |
| PPE | 0.707054 |
| cab | 0.49164 |
| alcohol-based hand rub | 0.362025 |
| infection control | 0.398637 |
| ambulance team members | 0.551178 |
| Ebola care facilities | 0.493482 |
| example | 0.361488 |
| Ambulance personnel | 0.398929 |
| personal belongings | 0.423865 |
| rubber boots | 0.365744 |
| disposable ppe | 0.50923 |
| biohazard waste bags | 0.421653 |
| Ebola outbreak. Teams | 0.405397 |
| direct contact | 0.367426 |
| tight fitting lids | 0.361771 |
| tight-fitting lid | 0.397816 |
| central ambulance maintenance | 0.48122 |
| Ambulance teams | 0.410008 |
| chlorine solution | 0.498067 |
| vehicle maintenance depot | 0.39722 |
| personal protective equipment | 0.373099 |
|
| easily cleanable materials | 0.362294 |
| World Health Organization | 0.36228 |
| basic infection control | 0.36562 |
| patients | 0.4162 |
| liquid waste | 0.362665 |
| appropriate ppe | 0.524088 |
| ambulance | 0.745712 |
| body fluids | 0.49874 |
| facility protocol | 0.404279 |
| ambulance team member | 0.433862 |
| patient care equipment | 0.366845 |
| centralized vehicle maintenance | 0.395805 |
| decontamination teams | 0.374003 |
| medical waste container | 0.360812 |
| Ebola care facility | 0.995924 |
| reusable equipment | 0.393426 |
| reusable ppe | 0.447185 |
| injuries. Ebola | 0.37502 |
| Vehicle cleaning | 0.363894 |
| disposable waste | 0.36824 |
| ambulance maintenance depot | 0.529978 |
| Ambulance service providers | 0.440652 |
| face shield | 0.360444 |
|
CLICK HERE |
| 12311 |
Centers for Disease Control and Prevention |
Html |
en |
CDC: Flu Activity Expands; Severity Similar to Past H3N2Seasons |
CDC recommends vaccination and rapid treatment with antiviral drugs for people at high risk from flu |
| epidemic threshold | 0.305374 |
| CDC | 0.380691 |
| overall flu-related hospitalizations | 0.312748 |
| ILI | 0.338302 |
| similar ILI trajectory | 0.32959 |
| flu activity | 0.551855 |
| flu vaccines | 0.55242 |
| highest ILI curve | 0.326783 |
| season | 0.789545 |
| flu hospitalization rates | 0.541865 |
| flu vaccination | 0.429115 |
| 2012-2013 flu season | 0.501427 |
| influenza-like illness rises | 0.310348 |
| Final vaccine uptake | 0.33191 |
| predominant flu viruses | 0.547957 |
| Flu Vaccine Finder | 0.503336 |
| flu spreads | 0.417755 |
| flu illness | 0.482441 |
| H3N2 viruses | 0.346682 |
| flu antiviral drugs | 0.709951 |
| flu pediatric deaths | 0.515097 |
| overall hospitalization rate | 0.318739 |
| past H3N2-predominant seasons | 0.325781 |
| current season | 0.377881 |
|
| different flu seasons | 0.465666 |
| vaccine effectiveness | 0.374148 |
| ILI activity | 0.316512 |
| flu-associated pediatric deaths | 0.39948 |
| high risk | 0.463244 |
| 2012-2013 season | 0.364037 |
| Influenza antiviral drugs | 0.340296 |
| influenza | 0.371832 |
| United States | 0.319781 |
| flu vaccine | 0.588211 |
| flu complications | 0.503033 |
| pediatric flu deaths | 0.601282 |
| previous flu seasons | 0.474662 |
| past severe seasons | 0.310467 |
| vaccine viruses | 0.324986 |
| latest CDC FluView | 0.343534 |
| certain health conditions | 0.312847 |
| total number | 0.360101 |
| flu seasons | 0.507034 |
| seasonal flu vaccine | 0.50208 |
| end-of-season hospitalization rate | 0.321644 |
| flu viruses | 0.586184 |
| people | 0.508774 |
| flu | 0.950755 |
|
CLICK HERE |
| 12750 |
Centers for Disease Control and Prevention |
Html |
en |
Preventing Chronic Disease | Patient Perspectives on TobaccoUse Treatment in Primary Care - CDC |
Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange on the very latest in chronic disease prevention, research findings, public health interventions, and the exploration of new theories and concepts.
|
| North Carolina | 0.883483 |
| smoking cessation interventions | 0.79884 |
| outcome measures | 0.772176 |
| health care provider | 0.707213 |
| Cancer Research Fund | 0.715588 |
| smoking cessation program | 0.7451 |
| tobacco cessation counselor | 0.711471 |
| National Health Interview | 0.710605 |
| quit attempt | 0.693786 |
| carbon monoxide monitoring | 0.802865 |
| regional smoking rate | 0.703723 |
| Disease Control | 0.722613 |
| tobacco users | 0.805354 |
| health care providers | 0.813866 |
| inductive coding techniques | 0.734513 |
| primary care practices | 0.710921 |
| primary care practice | 0.710621 |
| current smoking | 0.693657 |
| current cigarette smoking | 0.711074 |
| Morb Mortal Wkly | 0.748942 |
| important patient-centered outcomes | 0.765997 |
| patients | 0.73717 |
| carbon monoxide | 0.81164 |
| patient-centered smoking cessation | 0.801392 |
| office-based smoking cessation | 0.744948 |
|
| Health Interview Survey | 0.709972 |
| University Cancer Research | 0.717215 |
| smoking cessation | 0.944082 |
| patient-centered outcome measures | 0.755766 |
| primary care visit | 0.751027 |
| smoking cessation services | 0.748844 |
| United States | 0.713926 |
| health care insurance | 0.708307 |
| smokers | 0.73256 |
| relevant patient-centered outcome | 0.693528 |
| MMWR Morb Mortal | 0.748946 |
| primary care clinics | 0.817588 |
| future cessation research | 0.726394 |
| focus groups | 0.790205 |
| Mortal Wkly Rep | 0.743823 |
| health care | 0.853121 |
| participants | 0.806586 |
| primary care patients | 0.719974 |
| health care systems | 0.695401 |
| tobacco cessation interventions | 0.74633 |
| Chapel Hill | 0.745164 |
| creative patient-centered outcome | 0.70094 |
| various quit options | 0.715122 |
| primary care | 0.897588 |
|
CLICK HERE |
| 13563 |
Centers for Disease Control and Prevention |
Video |
en |
BRCA Genes and Breast Cancer |
Genetic counselor Joyce Turner, MSC, CGC, provides an overview of BRCA genes and their relationship to breast and ovarian cancer. She explains how each of us inherits BRCA genes from our parents, the role of those genes and what happens if we inherit a gene mutation. She also talks about how genetic counseling and testing can give a woman information she can use to make decisions about her health.
Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html
This video can also be viewed at
http://www.cdc.gov/cancer/videos/breast/BringYourBrave/Genetic_Counselor/BRCAGenesBreastCancer/BRCAGenesBreastCancer_lowRes.mp4 |
|
|
CLICK HERE |
| 15254 |
Centers for Disease Control and Prevention |
Html |
en |
Five Minute Weekly Tip Be Summer-Savvy - Family Health - CDC |
Family health information from the Centers for Disease Control and Prevention (CDC) |
| Summer | 0.622599 |
| health | 0.617695 |
|
| safety challenges | 0.980922 |
|
CLICK HERE |
| 16386 |
Centers for Disease Control and Prevention |
Html |
en |
Use of a 2-Dose Schedule for Human PapillomavirusVaccination - Updated Recommendations of the Advisory Committee onImmunization Practices | MMWR |
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC). |
| hpv vaccine | 0.971464 |
| HPV vaccine efficacy | 0.621142 |
| immunization practices | 0.53085 |
| HPV Vaccine Study | 0.584759 |
| ACIP meetings | 0.480138 |
| Human papillomavirus vaccination | 0.502846 |
| HPV-16/18 AS04-adjuvanted vaccine | 0.485183 |
| special populations | 0.505477 |
| advisory committee | 0.529965 |
| 15th birthday | 0.505699 |
| HPV vaccination recommendations | 0.670217 |
| additional vaccination | 0.483161 |
| 3-dose series | 0.550057 |
| clinical trial | 0.476603 |
| Vaccine Adverse Event | 0.489667 |
| ACIP HPV Vaccines | 0.624244 |
| 3-dose schedule | 0.524091 |
| medical conditions | 0.504143 |
| HPV vaccination series | 0.625511 |
| HPV infections | 0.572823 |
| human papillomavirus vaccine | 0.490247 |
| HPV vaccination†| 0.540851 |
| 9-valent HPV vaccine | 0.588396 |
| HPV exposure | 0.525234 |
| vaccination schedule | 0.499328 |
|
| doses | 0.689297 |
| HPV vaccination | 0.833932 |
| United States | 0.506347 |
| Vaccines Work Group | 0.496784 |
| ACIP HPV vaccination | 0.701686 |
| routine HPV vaccination | 0.755294 |
| CVT Vaccine Group | 0.491467 |
| quadrivalent HPV vaccine | 0.583565 |
| vaccine dose | 0.485675 |
| GRADE evidence type | 0.491553 |
| 9-valent human papillomavirus | 0.485888 |
| 9-valent HPV vaccines | 0.581999 |
| vaccine-preventable HPV types | 0.561704 |
| 2-dose series | 0.533562 |
| voting ACIP members | 0.500358 |
| CDC vaccine recommendations | 0.503898 |
| 2-dose schedule | 0.612163 |
| hpv vaccines | 0.643465 |
| HPV infection | 0.56278 |
| ACIP meeting | 0.479912 |
| Routine vaccination | 0.498442 |
| Bivalent HPV vaccine | 0.629493 |
| et al | 0.563042 |
| 3-dose HPV vaccine | 0.603665 |
|
CLICK HERE |